[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359256-105":59,"doc-detail-359256-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-and-clinical-impact-of-smoking-on-therapeutic-outcomes-in-prostate-cancer-a-public-databases-analysis","Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis","","Smoking history in prostate cancer is linked to more aggressive clinicopathological features, diminished androgen deprivation therapy efficacy, and worse overall survival, yet its effects across taxane chemotherapy, PARP inhibitor, and immune checkpoint inhibitor regimens remain uncertain. This study retrospectively compared smokers and non-smokers using genetic, treatment, and survival data from three public databases to evaluate associations with tumor genomics, clinicopathological variables, and independent risk factors for overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-and-clinical-impact-of-smoking-on-therapeutic-outcomes-in-prostate-cancer-a-public-databases-analysis/359256/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-and-clinical-impact-of-smoking-on-therapeutic-outcomes-in-prostate-cancer-a-public-databases-analysis/359256.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical and genomic differences were observed between smokers and non-smokers with prostate cancer?","Question",{"text":112,"@type":113},"Smokers showed higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non-smokers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did smoking history affect overall survival across treatment cohorts?",{"text":117,"@type":113},"Smokers had significantly poorer overall survival in the overall, hormone therapy, and PARPi therapy cohorts, while no significant difference was seen between taxane chemotherapy and ICI therapy cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors independently predicted overall survival in the study?",{"text":121,"@type":113},"Multivariate Cox proportional hazards analysis identified smoking history as an independent risk factor for overall survival in the overall, hormone therapy, and PARPi therapy cohorts, along with higher TP53 mutation frequency and PTEN copy number alterations in smokers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359256,1790449683,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Prostate   \nORIGINAL ARTICLE   \nGenomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis  \nTomoya Hatayama1  | Yohei Sekino1  | Go Kobayashi2 | Kazuma Yukihiro1 | Yoshinori Nakano1 | Shinsaku Tasaka1 | Naofumi Nomura1 | Yuki Kohada1 | Kenshiro Takemoto1  | Miki Naito1  | Shunsuke Miyamoto1  |  \nKohei Kobatake1  | Hiroyuki Kitano1  | Keisuke Goto1 | Akihiro Goriki1 | Keisuke Hieda1 | Nobuyuki Hinata1   \n1Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan | 2Laboratory of Molecular Pathology, Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan  \nCorrespondence: Yohei Sekino ([swimming@hiroshima-u.ac.jp](swimming@hiroshima-u.ac.jp))  \nReceived: 18 September 2025 | Revised: 1 January 2026 | Accepted: 16 January 2026  \nKeywords: biomarker | genomic mutation | prostate cancer | smoking  \nABSTRACT  \nBackground: In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS) . However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune checkpoint inhibitor (ICI) therapy for PCa remains unclear. We compared the genetic profiles of smokers and non‐smokers with PCa in several public databases to explore the potential influence of smoking on treatment outcomes.  \nMethods: We retrospectively collected data on smoking history, tumor characteristics, genomic information, treatment history, and survival outcomes from three public databases to investigate the role of smoking in PCa. Patients were categorized into smokers and non‐smokers, and associations between smoking history and clinicopathological features, genetic profiles, and treatment outcomes were analyzed. Independent risk factors for OS were evaluated using multivariate Cox proportional hazard regression models.  \nResults: Smokers exhibited significantly higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non‐smokers. The survival analysis revealed that smokers had significantly poorer OS than non‐smokers in the overall, hormone therapy, and PARPi therapy cohorts. In contrast, no significant difference in OS was observed between the taxane chemotherapy and ICI therapy cohorts. Furthermore, multivariate Cox proportional hazard regression analysis identified smoking history as an independent risk factor for OS in the overall, hormone therapy, and PARPi therapy cohorts. Oncoplot analysis showed a significantly higher frequency of TP53 mutations and PTEN copy number alterations in smokers than in non‐smokers.  \nConclusions: Smoking history was significantly associated with aggressive clinicopathological features and a poor prognosis inpatients with PCa. Our findings suggest that smokers with PCa may receive greater benefit from the early administration of taxane chemotherapy in comparison to other treatment regimens.  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s) . The Prostate published by Wiley Periodicals LLC.  \nThe Prostate, 2026; 86:689–696 689  \n[https://doi.org/10.1002/pros.70134](https://doi.org/10.1002/pros.70134)  \n1 | Introduction  \nSmoking increases the risk of occurrence and progression of several cancers [ 1] . Tobacco and tobacco smoke contain more than 16 and 60 carcinogens, respectively. In particular, tobacco smoke has been demonstrated to induce a more malignant phenotype by activating such as cancer cell proliferation, invasion, and migration. Among these, tobacco‐ specific N‐nitrosamines, polycyclic aromatic h","cbCaif6qVM5no1tq","https://ap.wps.com/l/cbCaif6qVM5no1tq","pdf",1694535,"English","# ABSTRACT\n## Background\n## Methods\n## Results\n## Conclusions\n# 1 | Introduction\n# 2 | Materials and Methods\n## 2.1 | Public Databases","[{\"question\":\"What clinical and genomic differences were observed between smokers and non-smokers with prostate cancer?\",\"answer\":\"Smokers showed higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non-smokers.\"},{\"question\":\"How did smoking history affect overall survival across treatment cohorts?\",\"answer\":\"Smokers had significantly poorer overall survival in the overall, hormone therapy, and PARPi therapy cohorts, while no significant difference was seen between taxane chemotherapy and ICI therapy cohorts.\"},{\"question\":\"Which factors independently predicted overall survival in the study?\",\"answer\":\"Multivariate Cox proportional hazards analysis identified smoking history as an independent risk factor for overall survival in the overall, hormone therapy, and PARPi therapy cohorts, along with higher TP53 mutation frequency and PTEN copy number alterations in smokers.\"}]","Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis | PDF",1790136524,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72e242767bc72bbe1434de635eb3ddbc.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b78c2113eae6db4e8b4be1b2dfeb37dc.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0b8cb7e5dee06d8826819d7f915b407.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1da3d82ef871bfb3daa8990161d4cba.webp",980,1287]